Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 18/20 | 0.71 |
| ▸ | LCK | P06239 | 16/20 | 0.71 |
| ▸ | EGFR | P00533 | 10/20 | 0.67 |
| ▸ | BTK | Q06187 | 14/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21946363 | 0.99 | JAK3 (0.72) | JAK3LCKEGFRBTK | |
| SCHEMBL30448210 | 0.99 | JAK3 (0.72) | JAK3LCKEGFRBTK | |
| SCHEMBL21946887 | 0.93 | JAK3 (0.64) | JAK3LCKEGFRBTK | |
| SCHEMBL21946361 | 0.92 | JAK3 (0.68) | JAK3LCKEGFRBTK | |
| SCHEMBL30448986 | 0.92 | JAK3 (0.68) | JAK3LCKEGFRBTK | |
| SCHEMBL26970114 | 0.92 | JAK3 (0.65) | JAK3LCKEGFRBTK | |
| SCHEMBL21855172 | 0.92 | JAK3 (0.65) | JAK3LCKEGFRBTK | |
| SCHEMBL31037956 | 0.92 | JAK3 (0.65) | JAK3LCKEGFRBTK | |
| SCHEMBL31039886 | 0.91 | JAK3 (0.64) | JAK3LCKEGFRBTK | |
| SCHEMBL21946819 | 0.91 | JAK3 (0.64) | JAK3LCKEGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416242-A1 | DOUBLE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4232059-A1 | DOUBLE DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| WO-2022087216-A1 | DOUBLE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022087216-A1 | DOUBLE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2021113557-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416242-A1 | DOUBLE DEGRADERS AND USES THEREOF | DCXR, IDUA, GUSB | JAK3 3036/4885LCK 4130/4885EGFR 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.